These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 26341321

  • 1. Physical stability of drugs after storage above and below the glass transition temperature: Relationship to glass-forming ability.
    Alhalaweh A, Alzghoul A, Mahlin D, Bergström CAS.
    Int J Pharm; 2015 Nov 10; 495(1):312-317. PubMed ID: 26341321
    [Abstract] [Full Text] [Related]

  • 2. Early drug development predictions of glass-forming ability and physical stability of drugs.
    Mahlin D, Bergström CA.
    Eur J Pharm Sci; 2013 May 13; 49(2):323-32. PubMed ID: 23557841
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Physical (In)Stability of Spray-Dried Amorphous Drugs: Relationship with Glass-Forming Ability and Physicochemical Properties.
    Edueng K, Bergström CAS, Gråsjö J, Mahlin D.
    Pharmaceutics; 2019 Aug 21; 11(9):. PubMed ID: 31438566
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses.
    Zhou D, Grant DJ, Zhang GG, Law D, Schmitt EA.
    J Pharm Sci; 2007 Jan 21; 96(1):71-83. PubMed ID: 17031846
    [Abstract] [Full Text] [Related]

  • 6. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin.
    Zhou D, Zhang GG, Law D, Grant DJ, Schmitt EA.
    Mol Pharm; 2008 Jan 21; 5(6):927-36. PubMed ID: 19434849
    [Abstract] [Full Text] [Related]

  • 7. Glass-forming ability of compounds in marketed amorphous drug products.
    Wyttenbach N, Kuentz M.
    Eur J Pharm Biopharm; 2017 Mar 21; 112():204-208. PubMed ID: 27903457
    [Abstract] [Full Text] [Related]

  • 8. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature.
    Yoshioka M, Hancock BC, Zografi G.
    J Pharm Sci; 1994 Dec 21; 83(12):1700-5. PubMed ID: 7891297
    [Abstract] [Full Text] [Related]

  • 9. Crystallization kinetics and molecular mobility of an amorphous active pharmaceutical ingredient: A case study with Biclotymol.
    Schammé B, Couvrat N, Malpeli P, Delbreilh L, Dupray V, Dargent É, Coquerel G.
    Int J Pharm; 2015 Jul 25; 490(1-2):248-57. PubMed ID: 26003417
    [Abstract] [Full Text] [Related]

  • 10. Influence of preparation pathway on the glass forming ability.
    Blaabjerg LI, Lindenberg E, Rades T, Grohganz H, Löbmann K.
    Int J Pharm; 2017 Apr 15; 521(1-2):232-238. PubMed ID: 28232267
    [Abstract] [Full Text] [Related]

  • 11. Molecular Dynamics and Physical Stability of Pharmaceutical Co-amorphous Systems: Correlation Between Structural Relaxation Times Measured by Kohlrausch-Williams-Watts With the Width of the Glass Transition Temperature (ΔTg) and the Onset of Crystallization.
    Chieng N, Teo X, Cheah MH, Choo ML, Chung J, Hew TK, Keng PS.
    J Pharm Sci; 2019 Dec 15; 108(12):3848-3858. PubMed ID: 31542436
    [Abstract] [Full Text] [Related]

  • 12. What Are the Important Factors That Influence API Crystallization in Miscible Amorphous API-Excipient Mixtures during Long-Term Storage in the Glassy State?
    Newman A, Zografi G.
    Mol Pharm; 2022 Feb 07; 19(2):378-391. PubMed ID: 34378939
    [Abstract] [Full Text] [Related]

  • 13. Glass transition and enthalpy relaxation of amorphous lactose glass.
    Haque MK, Kawai K, Suzuki T.
    Carbohydr Res; 2006 Aug 14; 341(11):1884-9. PubMed ID: 16709405
    [Abstract] [Full Text] [Related]

  • 14. A classification system to assess the crystallization tendency of organic molecules from undercooled melts.
    Baird JA, Van Eerdenbrugh B, Taylor LS.
    J Pharm Sci; 2010 Sep 14; 99(9):3787-806. PubMed ID: 20623696
    [Abstract] [Full Text] [Related]

  • 15. An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: A case study with dipyridamole and cinnarizine.
    Baghel S, Cathcart H, Redington W, O'Reilly NJ.
    Eur J Pharm Biopharm; 2016 Jul 14; 104():59-71. PubMed ID: 27108783
    [Abstract] [Full Text] [Related]

  • 16. Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation.
    Blaabjerg LI, Lindenberg E, Löbmann K, Grohganz H, Rades T.
    Mol Pharm; 2016 Sep 06; 13(9):3318-25. PubMed ID: 27529364
    [Abstract] [Full Text] [Related]

  • 17. Impact of chirality on the Glass Forming Ability and the crystallization from the amorphous state of 5-ethyl-5-methylhydantoin, a chiral poor glass former.
    Atawa B, Couvrat N, Coquerel G, Dargent E, Saiter A.
    Int J Pharm; 2018 Apr 05; 540(1-2):11-21. PubMed ID: 29407191
    [Abstract] [Full Text] [Related]

  • 18. An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature.
    Qi S, Weuts I, De Cort S, Stokbroekx S, Leemans R, Reading M, Belton P, Craig DQ.
    J Pharm Sci; 2010 Jan 05; 99(1):196-208. PubMed ID: 19492312
    [Abstract] [Full Text] [Related]

  • 19. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures.
    Hancock BC, Shamblin SL, Zografi G.
    Pharm Res; 1995 Jun 05; 12(6):799-806. PubMed ID: 7667182
    [Abstract] [Full Text] [Related]

  • 20. Relationship between crystallization tendencies during cooling from melt and isothermal storage: toward a general understanding of physical stability of pharmaceutical glasses.
    Kawakami K, Harada T, Miura K, Yoshihashi Y, Yonemochi E, Terada K, Moriyama H.
    Mol Pharm; 2014 Jun 02; 11(6):1835-43. PubMed ID: 24731254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.